AM
Ashish Mandelia
VP, Chief Accounting Officer

Ashish Mandelia insider trades: Mersana Therapeutics (MRSN) stock buys and sales

VP, Chief Accounting Officer, Mersana Therapeutics Last trade Jan 16, 2025 14 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2020
1
Company
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Ashish reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 16, 2025MRSN↓ Sell$2K
Jan 15, 2025MRSN↓ Sell$1K
Jan 14, 2025MRSN↓ Sell$665
Oct 3, 2024MRSN↓ Sell$16K
Jan 16, 2024MRSN↓ Sell$14K
Jan 17, 2023MRSN↓ Sell$21K
Jan 18, 2022MRSN↓ Sell$12K
Jul 1, 2021MRSN↓ Sell$13K
Jan 19, 2021MRSN↓ Sell$12K
Jan 4, 2021MRSN↓ Sell$7K
Jul 2, 2020MRSN↓ Sell$76K
Jun 30, 2020MRSN↑ Buy$16K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Ashish Mandelia's insider trades

Ashish Mandelia is VP, Chief Accounting Officer at Mersana Therapeutics (MRSN). Since Jun 30, 2020, Ashish has reported 1 open-market purchase worth $16K and 11 sales worth $173K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include option exercises (8 filings), grants and awards (7 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MRSN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.